Cholesterol, Statins, and How to Think About Cardiovascular Risk

A cholesterol result of 6.8 arrives by letter, sits on the kitchen table for a week, and provokes one of two reactions. Either quiet alarm — is this the number that gives people heart attacks? — or a shrug, because nothing about it can be felt. Both reactions miss the same thing. A cholesterol value in isolation is not a verdict. It is one ingredient in a calculation, and the calculation is the part that actually matters.

The single most useful shift in thinking here is to stop asking whether a number is "high" and start asking a harder question: given everything about me — age, sex, blood pressure, smoking, diabetes, family history, and yes, cholesterol — what is the chance I have a heart attack or stroke in the next ten years, and what moves that chance down? That question is the whole of modern cardiovascular prevention. The cholesterol number is a character in the story, not the plot.

What the lipid panel is actually telling you

"Cholesterol" on a lab report is rarely a single figure. A standard lipid panel breaks it into parts, and the parts behave very differently.

LDL cholesterol — low-density lipoprotein — is the fraction that, in excess and over time, deposits in artery walls and drives the slow build-up of atherosclerotic plaque. When clinicians talk about "lowering cholesterol" to reduce cardiovascular risk, this is overwhelmingly the fraction they mean. The causal link between lifelong LDL exposure and arterial disease is one of the better-established relationships in medicine.

HDL cholesterol — high-density lipoprotein — was long described as "good cholesterol," shorthand that has aged badly. Higher HDL tracks with lower risk in populations, but raising it with drugs has stubbornly failed to reduce events in trials, which suggests it is more a marker of underlying health than a lever to pull.

Triglycerides are a separate fat fraction influenced heavily by weight, alcohol, and blood sugar control; very high levels carry their own risks. And non-HDL cholesterol — total cholesterol minus HDL — has quietly become a preferred summary measure in UK guidance, because it captures all the harmful fractions in one number without needing a fasting sample.

The practical point: a "total cholesterol" of 6.8 could reflect very different risk pictures depending on what it is made of. The breakdown matters more than the headline.

Risk is a calculation, not a threshold

This is why UK practice does not treat a cholesterol number as an automatic trigger for anything. Instead, clinicians estimate overall ten-year cardiovascular risk using a tool such as QRISK, which folds cholesterol in alongside age, sex, ethnicity, blood pressure, smoking, diabetes, body mass index, and family history. Two people with identical cholesterol can have wildly different risk — a 35-year-old non-smoker and a 65-year-old smoker with high blood pressure are not in the same conversation, whatever their lipid panels say.

Guidelines then use that overall risk, not the cholesterol alone, to frame whether a cholesterol-lowering medicine is worth discussing. It is a fundamentally different logic from "your number is over the line, so here is a tablet." It asks instead: across someone with this whole profile, does lowering LDL meaningfully reduce the chance of a serious event? Sometimes the cholesterol is modest but the overall risk is high; sometimes the cholesterol looks alarming but sits in an otherwise low-risk person. The number rarely speaks for itself.

The statin evidence, fairly stated

Statins are among the most heavily studied medicines in existence, and pretending otherwise — in either direction — does readers a disservice. The Cholesterol Treatment Trialists' (CTT) collaboration, which pooled individual data from many large randomised trials involving hundreds of thousands of participants, found that lowering LDL with a statin reduces the risk of major vascular events, with the benefit broadly proportional to how much LDL falls and how long treatment continues. That is a genuinely strong evidence base — large, randomised, replicated, and consistent.

What the benefit means for a given person, though, depends entirely on their baseline risk. The same proportional risk reduction translates into a large absolute benefit for someone at high risk and a small one for someone at low risk. This is exactly why the decision returns, again, to overall risk rather than the cholesterol figure.

The side-effect debate, handled honestly

No medicine is free of trade-offs, and statins attract more debate about side effects than almost any other drug. Here the evidence deserves careful, even-handed reading rather than slogans.

Muscle aches are the most reported complaint. They are real experiences and worth taking seriously. What the trial evidence shows is more nuanced than either camp claims: in blinded studies, where neither participant nor researcher knew who was taking a statin, the rate of muscle symptoms was only marginally higher on the drug than on placebo — far lower than the rate reported in everyday practice. Some clever "n-of-1" studies, in which people who had stopped statins because of side effects were randomly switched between statin and placebo without knowing which was which, found that many experienced the same symptoms on placebo. This points to a strong nocebo effect — symptoms genuinely felt, but driven partly by expectation rather than the drug itself.

The honest reading is neither "statins are poison" nor "side effects are imaginary." Symptoms are real and sometimes drug-related; serious muscle problems do occur but are rare; and a meaningful share of reported intolerance has a nocebo component that can sometimes be worked through with a clinician — by changing dose or trying a different statin. None of that is something to navigate from an article. It is precisely the kind of individual problem-solving a prescriber who knows your history is for.

Statins are not the only tool

Cholesterol-lowering is also no longer a one-drug conversation. Where a statin is not tolerated or not enough, other options exist — ezetimibe, and newer injectable agents that lower LDL substantially. Lifestyle remains foundational throughout: dietary pattern, weight, activity, and not smoking all shape the wider risk picture, even if their effect on LDL specifically is more modest than medicine's. The existence of alternatives is reassuring, but which, if any, suits a particular person is — predictably by now — an individual clinical judgement.

Practical takeaways

• A cholesterol number in isolation is not a diagnosis; overall ten-year cardiovascular risk is the figure that actually drives decisions.
• LDL (or non-HDL) cholesterol is the fraction most linked to arterial disease; "total cholesterol" can hide very different pictures.
• The statin evidence base is large, randomised, and consistent: lowering LDL reduces major vascular events, with absolute benefit scaling to baseline risk.
• The side-effect debate is real but nuanced — muscle symptoms are common reports, frequently have a nocebo component, and serious harm is rare.
• Statins are not the only option, and the right approach for any individual is a conversation, not a formula.

What this doesn't mean

It does not mean everyone with a raised cholesterol needs medication, nor that anyone on a statin should reconsider it on the strength of a web article. It does not mean lifestyle is irrelevant, nor that it always substitutes for medicine. What your specific numbers and risk mean for you is a question for a clinician with your full history in front of them.

When to seek medical advice

If you have been offered a cholesterol or cardiovascular risk assessment, or have a strong family history of early heart disease, that is worth discussing with your GP. If you are taking a statin and experience troublesome symptoms, raise them with your prescriber or pharmacist rather than stopping on your own — and seek prompt advice for severe or widespread muscle pain, especially with dark urine or feeling generally unwell.

A closing thought

Cholesterol has spent decades as the villain of the cardiovascular story, which has made it both over-feared and over-simplified. The more useful frame is undramatic: it is one input into a risk calculation, that calculation can be estimated, and the things that move it — including, for the right person, a well-evidenced and much-debated little tablet — can be weighed honestly with someone who knows you. Risk is not a number on a letter. It is a conversation worth having.

Further reading and sources

• NICE NG238 — Cardiovascular disease: risk assessment and reduction, including lipid modification
• Cholesterol Treatment Trialists' (CTT) Collaboration — meta-analyses of statin trials
• British Heart Foundation — understanding cholesterol and statins
• HEART UK — the cholesterol charity
• European Society of Cardiology / European Atherosclerosis Society — guidelines on dyslipidaemias
• Cochrane — reviews of statins for primary prevention

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.